bluuebunny/crossref_metadata_2025_split huggingface dataset:
The molecular chaperone mtHSC70‐1 interacts with DjA30 to regulate female gametophyte development and fertility in Arabidopsis
Authors: Zhai Xiaoting , Bai Jiaoteng , Xu Wenyan , Yang Xiujuan , Jia Zichao , Xia Wenxuan , Wu Xiaoqing , Liang Qi , Li Bing , Jia Ning 
Published: June 2023

SUMMARYArabidopsis mitochondria‐targeted heat shock protein 70 (mtHSC70‐1) plays important roles in the establishment of cytochrome c oxidase‐dependent respiration and redox homeostasis during the vegetative growth of plants. Here, we report that knocking out the mtHSC70‐1 gene led to a decrease in plant fertility; the fertility defect of the mutant was completely rescued by introducing the mtHSC70‐1 gene. mtHSC70‐1 mutants also showed defects in female gametophyte (FG) development, including delayed mitosis, abnormal nuclear position, and ectopic gene expression in the embryo sacs. In addition, we found that an Arabidopsis mitochondrial J‐protein gene (DjA30) mutant, j30+/−, had defects in FG development and fertility similar to those of mtHSC70‐1 mutant. mtHSC70‐1 and DjA30 had similar expression patterns in FGs and interacted in vivo, suggesting that these two proteins might cooperate during female gametogenesis. Further, respiratory chain complex IV activity in mtHSC70‐1 and DjA30 mutant embryo sacs was markedly downregulated; this led to the accumulation of mitochondrial reactive oxygen species (ROS). Scavenging excess ROS by introducing Mn‐superoxide dismutase 1 or catalase 1 gene into the mtHSC70‐1 mutant rescued FG development and fertility. Altogether, our results suggest that mtHSC70‐1 and DjA30 are essential for the maintenance of ROS homeostasis in the embryo sacs and provide direct evidence for the roles of ROS homeostasis in embryo sac maturation and nuclear patterning, which might determine the fate of gametic and accessory cells.
Efficient granulocyte collection method using high concentrations of medium molecular weight hydroxyethyl starch
Authors: Kondo Takumi , Fujii Keiko , Fujii Nobuharu , Sumii Yuichi , Urata Tomohiro , Kimura Maiko , Matsuda Masayuki , Ikegawa Shuntaro , Washio Kana , Fujiwara Hideaki , Asada Noboru , Ennishi Daisuke , Nishimori Hisakazu , Matsuoka Ken‐ichi , Otsuka Fumio , Maeda Yoshinobu 
Published: June 2023

AbstractBackgroundGranulocyte transfusion therapy is a rational therapeutic option for patients with prolonged, severe neutropenia. Although high molecular weight hydroxyethyl starch (hHES) facilitates the separation of red blood cells during granulocyte collection, renal dysfunction has been noted as a potential side effect. HES130/0.4 (Voluven®) is a medium molecular weight HES (mHES) with superior safety profiles compared to hHES. Although HES130/0.4 is reportedly effective in the collection of granulocytes, we lack studies comparing the efficiency of granulocyte collection using HES130/0.4 and hHES.Study Design and MethodsWe retrospectively collected the data from 60 consecutive apheresis procedures performed on 40 healthy donors at the Okayama University Hospital between July 2013 and December 2021. All procedures were performed using the Spectra Optia system. Based on the HES130/0.4 concentration in the separation chamber, granulocyte collection methods using HES130/0.4 were classified into m0.46, m0.44, m0.37, and m0.8 groups. We used HES130/0.4 and hHES groups to compare the various sample collection methods.ResultsThe median granulocyte collection efficiency (CE) was approximately 24.0% and 28.1% in the m0.8 and hHES groups, respectively, which were significantly higher than those in the m0.46, m0.44, and m0.37 groups. One month following granulocyte collection with HES130/0.4, no significant changes were observed in serum creatinine levels compared to those before the donation.ConclusionTherefore, we propose a granulocyte collection approach employing HES130/0.4, which is comparable to the use of hHES in terms of the granulocyte CE. A high concentration of HES130/0.4 in the separation chamber was considered crucial for granulocyte collection.
Effect of Aerobic/Strength Training on RANKL Gene DNA Methylation Levels
Authors: Chelly Ameni , Bouzid Amal , Neifar Fadoua , Kammoun Ines , Tekari Adel , Masmoudi Saber , Chtourou Hamdi , Rebai Ahmed 
Published: June 2023

Background: The osteoclastogenesis RANKL gene plays a key role in bone remodeling. The hypomethylation of its promoter region may cause osteoporosis. The present study aimed to elucidate the influence of physical activity on DNA methylation changes of RANKL promoter cytosine-phosphate-guanine (CpG)-rich region in active and sedentary adults and to assess the effect of aerobic and strength training on RANKL DNA methylation changes among Tunisian-North African adults. Methods: A total of 104 participants including 52 adults (58% males and 42% females) and 52 adults (31% males and 69% females) were recruited for the observational and interventional part of the study, respectively. The intervention consisted of 12 weeks of aerobic training (30 min/session) followed by 10 minutes of strengthening exercises. All participants completed the International Physical Activity Questionnaire and provided blood samples for quantitative methylation-specific polymerase chain reaction (PCR) analysis. Results: The study revealed a significant difference (P = 6 × 10−10) in the methylation level of the RANKL promoter region between active and sedentary adults, with a 6.68-fold increase observed in the active group. After the intervention, both the trained (P = 41 × 10−5) and untrained (P = .002) groups displayed high methylation levels in the RANKL promoter region. In addition, the trained group exhibited significant improvements in heart rate (P = 2.2 × 10−16), blood pressure (P = 39 × 10−3), maximal oxygen uptake (P = 1.5 × 10−7), and fat mass (P = 7 × 10−4). Conclusion: Exploring epigenetic modifications in the RANKL promoter region may contribute to a more comprehensive understanding of the complexity of osteoporosis. This suggests that aerobic/strength training could potentially improve the bone system, reducing its vulnerability to osteoporosis by increasing RANKL DNA methylation.
Successful bailout stenting for critical aortic coarctation in a premature baby weighing 590 g
Authors: Matsuo Kumiyo , Asada Dai , Aoki Hisaaki , Kayatani Futoshi 
Published: June 2023

Severe aortic coarctation (CoA) is a critical congenital heart disease that requires surgery as the first-line treatment in neonates. However, in very small premature infants, aortic arch repair has a relatively high mortality and morbidity rate. Bailout stenting is an alternative method that can be performed safely and effectively with low morbidity.We present a case of severe CoA in a premature baby, a monochorionic twin with selective intrauterine growth restriction. The patient was born at 31 weeks of gestation with a birth weight of 570 g. Seven days following her birth, she experienced anuria due to critical neonatal isthmic CoA. She underwent a stent implantation procedure at term neonatal, weighing 590 g. She had good dilatation of the coarcted segment with no complications. Follow-up at infancy showed no CoA recurrence. This is the world’s smallest case of stenting for CoA.
Length of employment in workplaces handling hazardous chemicals and risk of cancer among Japanese men
Authors: Fukai Kota , Furuya Yuko , Nakazawa Shoko , Kojimahara Noriko , Hoshi Keika , Toyota Akihiro , Tatemichi Masayuki 
Published: June 2023

ObjectivesIn Japan, the risk of developing cancer among workers employed in workplaces where chemical substances are handled is unclear. This study aimed to assess the association between cancer risk and employment in workplaces handling hazardous chemicals.MethodsThe Inpatient Clinico-Occupational Survey of the Rosai Hospital Group data of 120 278 male patients with incident cancer and 217 605 hospital controls matched for 5-year age group, hospital (34 hospitals) and year of admission (2005–2019) were analysed. Cancer risk in relation to lifetime employment in workplaces using regulated chemicals was assessed while controlling for age, region and year of diagnosis, smoking, alcohol consumption and occupation. Further analysis stratified by smoking history was performed to examine interaction effects.ResultsIn the longest group of employment in tertiles, ORs were increased for all cancers (OR=1.13; 95% CI: 1.07 to 1.19) and lung (OR=1.82; 95% CI: 1.56 to 2.13), oesophageal (OR=1.73; 95% CI: 1.18 to 2.55), pancreatic (OR=2.03; 95% CI: 1.40 to 2.94) and bladder (OR=1.40; 95% CI: 1.12 to 1.74) cancers. Employment of 1+ years was associated with risk for lung cancer; 11+ years for pancreatic and bladder cancers; and 21+ years for all cancers and oesophageal cancer. These positive relationships were particularly obvious among patients with a history of smoking; however, no significant interaction between smoking and length of employment was observed.ConclusionsThere is a high risk of cancer among workers, especially smokers, employed in workplaces handling regulated chemicals in Japan. Thus, future measures for chemical management in workplaces are needed to prevent avoidable cancers.
A new look at the Dirac quantization condition
Authors: Dunia Michael , Hung P. Q. , Singleton Douglas 
Published: June 2023

AbstractThe angular momentum of any quantum system should be unambiguously quantized. We show that such a quantization fails for a pure Dirac monopole due to a previously overlooked field angular momentum from the monopole-electric charge system coming from the magnetic field of the Dirac string and the electric field of the charge. Applying the point-splitting method to the monopole-charge system yields a total angular momentum which obeys the standard angular momentum algebra, but which is gauge variant. In contrast it is possible to properly quantize the angular momentum of a topological ’t Hooft–Polyakov monopole plus charge. This implies that pure Dirac monopoles are not viable – only ’t Hooft–Polyakov monopoles are theoretically consistent with angular momentum quantization and gauge invariance.
Abstract 1: Mouse models of cancer available from The Jackson Laboratory
Authors: Beckwith Jason , Merriam Jen , Valenzuela Alicia , Pomerleau Darcy , Davis Crystal 
Published: June 2023

Abstract
Genetically defined mice are a cornerstone of cancer research. The Jackson Laboratory (JAX) offers more than 13,500 unique mouse lines to the scientific community, many useful in advancing cancer research. Available are mouse models for specific cancers, xenograft recipients, immunodeficient platforms for PDX studies and multi-purpose tool strains having CRISPR/Cas9 expression, conditional/inducible expression (Cre-lox, FLP-frt, Tet-On/-Off), optogenetic function and calcium-sensing technologies. This poster will highlight some recently added models, more than 150 of which have cancer research applications. The portfolio of strains useful for transplantation/engraftment and “humanized” mouse research continues to expand and complement the NSG (NOD scid IL2rγc-/-) model as ideal tools for engraftment with a wide range of malignant or non-malignant human or mouse tissues. Fluorescent protein-expressing strains include the Traffic Light Reporter models for tracking of DNA repair pathways and the Gene Editing Reporter models for detection of homology directed repair (HDR) or non-homologous end joining (NHEJ) repair events. As a tool for gene targeting, the RosaBxb-GT/GA mice are designed to allow insertion of ~40kb of desired DNA sequence into the Gt(ROSA)26Sor locus. In addition to safeguarding each strain by cryopreservation, JAX has a comprehensive genetic quality control program that confirms mutation identity and genetic background, and screens for unwanted alleles (such as stray GFP, Cre, neo, etc.). Search the comprehensive collection of innovative mouse models using our improved JAX Mouse Search site (mice.jax.org). This resource includes models created by many generous donating institutions. Researchers are encouraged to donate their mouse lines via a very short Strain Submission form (jax.org/donate-a-mouse). Please also visit the JAX Oncology webpage for cancer research related strains and resources (jax.org/jax-mice-and-services/solutions-by-therapeutic-area/oncology). JAX is supported by the NIH, The Howard Hughes Medical Institute and other private charitable foundations.
Citation Format: Jason Beckwith, Jen Merriam, Alicia Valenzuela, Darcy Pomerleau, Crystal Davis. Mouse models of cancer available from The Jackson Laboratory [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1.
Abstract 1006: Assessment of expression of microRNA-23b as a prognostic marker in cancer
Authors: Wadaaallah Ahmed Mahmoud , Sultan Ahmed Samir 
Published: June 2023

Abstract
Cancer is the major cause of death around the world. MiRNA-23b has been proposed to be expressed in various types of cancer. However, it’s prognostic role in several types of cancer has not been well identified. We conducted this meta-analysis to assess the associations between miRNA-23b expression and overall survival (OS) in various carcinoma. The current study presented the baseline characteristics and pooled survival results using a pooled hazard ratio (HR) with 95% confidence intervals (95% CI). Both Random and fixed effect models were conducted according to the heterogeneity of the analyzed. Then subgroup and publication bias analyses were executed. We identified a total sample size of 1589 in various carcinomas, including gastric (370), breast (203), ovarian (166), colorectal (206), renal (411), bladder (20), prostate (151) and lung cancer (62). The pooled HR of nine studies suggested that low miRNA-23b expression was obviously associated with worse OS (HR 3.2, 95% CI 2.26 to 4.53, P&lt;0.001) with a low statistical heterogeneity index (I2=53%, P=0.03) in most of cancer types. On the other hand, the other three remaining studies (gastric and breast cancer) showed that miRNA-23b high expression was associated with reduced OS (HR 1.59, 95%CI 1.07 to 2.37, P&lt;0.02) with no heterogeneity between the studies (I2=0%, P=0.38). All in all, our data showed that miRNA-23b was highly expressed in the plasma of breast and gastric cancer but was low expressed in most types of cancer. In addition, miRNA -23b expression is significantly associated with poor overall survival in several cancer types and might be considered as a potential prognostic marker.
Citation Format: Ahmed Mahmoud Wadaaallah, Ahmed Samir Sultan. Assessment of expression of microRNA-23b as a prognostic marker in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1006.
Abstract 1061: Digital phenotyping in pediatric oncology: the development of a mobile application for outpatients follow up
Authors: Elmoneim Abeer Abd , Aly Marwan 
Published: June 2023

Abstract
Introduction and aim: Outpatients follow up usually depends on recall of data. This recall is subjective to patients' or gaurdians' memory. Smart phones can capture a lot of data either through inbuilt sensors and connected devices or through the engagement of users. These mobile digital devices brought forth innovative methods of acquiring personal healthcare data. In pediatric oncology, the need for accurate record of serious symptoms while patients are at home is a challenge in outpatients' care. In a step towards collecting real-time events that happened during the outpatient follow up, we develop a smart phone application that can record data actively by patients or their guardians in situ and on time of its occurrence, which can improve the follow up process and facilitate a decision making by the physician that based on objective data more than subjective ones. We aim in this research to generate an easy-to-use mobile application for home follow up of pediatric oncology patients.
Methods: Predictive characteristics of digital features either extracted from studies or generated by field experts were reported to map the associations between digital feature and the disease. Identified digital features were aggregated into categories that represent interpretable serious signs. A smart phone application with the identified digital features is developed with the help of Valid Solutions, LLC (Health Technology Limited Liability Company, USA).
Expected Results: Early and accurate detection of serious symptoms through in situ and on real-time can help to better delivery of required health care.
Conclusion: This research will provide a high level vision on relationships between digital phenotyping and pediatric oncology illnesses and will help to identify gaps requiring further research. It will highlight the digital features with higher value of prediction of serious signs.
Citation Format: Abeer Abd Elmoneim, Marwan Aly. Digital phenotyping in pediatric oncology: the development of a mobile application for outpatients follow up [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1061.
Abstract 1073: PRMT5 inhibition synergizes with a natural small molecule compound to kill MTAP-deleted cells and suppress tumor growth
Authors: Barekatain Yasaman , LaBella Kyle , Sugimoto Hikaru , Harris Kristen , Khadka Sunada , Muller Florian , Kalluri Raghu 
Published: June 2023

Abstract
Homozygous deletion of MTAP occurs in about 15% of all human cancers, such as glioblastoma, pancreatic cancer, mesothelioma, urothelial bladder carcinoma, and lung squamous cell carcinoma. PRMT5 inhibitors show activity against MTAP-deleted cancer cells in culture and xenografts with a mechanism that relies on the significant elevation of the MTAP substrate, methylthioadenosine (MTA). Previously, we have shown that unlike cells in culture, MTA levels in MTAP-deleted primary human GBM tumors are not significantly higher than in MTAP-intact tumors. Therefore, combining the PRMT5 inhibitor with another drug may be required to increase the therapeutic window and clinical efficacy of a PRMT5 inhibitor in MTAP-deleted patients. Here, we identified a natural small molecular chemical compound with a good safety profile that synergizes with a PRMT5-MTA complex inhibitor, which boosts the efficacy of MTAP-deleted selective cell killing in the presence of MTA sequestering cells. This combination therapy significantly increases the potency of PRMT5 inhibitor treatment in MTAP-deleted cells across various tumor cell lines and lowers the IC50 of PRMT5 inhibitor treatment. In vivo, PRMT5 inhibitor combination treatment leads to smaller tumor volumes in MTAP-deleted CDX tumors (U87, glioma cell line) compared to PRMT5 inhibitor monotherapy. In summary, our proposed combination therapy of PRMT5 inhibition with a natural compound may increase the therapeutic window and clinical efficacy of PRMT5 inhibitors leading to better treatment options for patients harboring MTAP-deleted cancer.
Citation Format: Yasaman Barekatain, Kyle LaBella, Hikaru Sugimoto, Kristen Harris, Sunada Khadka, Florian Muller, Raghu Kalluri. PRMT5 inhibition synergizes with a natural small molecule compound to kill MTAP-deleted cells and suppress tumor growth [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1073.
Abstract 111: Characterizing subpopulation response to doxorubicin in a barcode-labeled triple negative breast carcinoma cell line
Authors: Morgan Daylin , Brock Amy 
Published: June 2023

Abstract
Despite recent advances in diagnosis and late-stage treatment, progression-free survival is not achieved for many cancer patients. Triple negative breast cancer (TNBC) poses a particular challenge as an aggressive and heterogeneous disease lacking the benefit of hormonal therapies. We have utilized a novel genetic lineage-tracking system, ClonMapper in TNBC cells to elucidate the pre-existent and de novo cell states that arise from chemotherapeutic intervention.
ClonMapper genetic tags were stably integrated into MDA-MB-231 cells using lentiviral transduction and positively labeled cells were isolated with fluorescence-activated cell sorting to generate a starting library of ~500 uniquely barcoded cells. Barcode-labeled MDA-MB-231 were selected with doxorubicin at 250, 400 and 550 nM for 48 hours and allowed to recover. To determine the contribution of transcriptomic state to cellular drug response we carried out single cell RNA-sequencing (scRNA-seq) on 4 populations: a pretreatment cell library, an intermediary taken 30 h into drug selection, and two recovered populations from the 250 nM group. Importantly, we are able to capture and deconvolve ClonMapper lineage tags from scRNA-seq results and overlay them with transcriptomic state.
Following treatment with doxorubicin we found a dose-dependent reduction in the number of unique lineages, with all replicates showing &gt;6-fold decrease. Post-treatment replicates were each significantly comprised (90%) by fewer than three individual lineages. Lineage-resolved transcriptomics revealed two distinct lineage-specific subpopulations within the pretreatment cell library. These subpopulations demonstrated unique survivorship trajectories, beginning 30 h into selection and remaining well-separated following recovery from treatment. Comparing these subpopulations directly we observe enrichment for several pathways with markers genes remaining highly expressed post-treatment. Crucially, both subpopulations harbor a unique set of lineages which are found to survive treatment. However, in the absence of treatment we find that one subpopulation displays a faster growth rate and is likely to outcompete the other in culture conditions. The more proliferative subpopulation is marked by enrichment of Myc targets, compared with enrichment of glycolysis and KRAS signaling in the less proliferative subpopulation. This data demonstrates that subclonal heterogeneity inherent within this TNBC cell model, drives differential cell responses to chemotherapy.
Citation Format: Daylin Morgan, Amy Brock. Characterizing subpopulation response to doxorubicin in a barcode-labeled triple negative breast carcinoma cell line [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 111.